France Neurology Clinical Trials Market Report 2022 to 2030

France Neurology Clinical Trials Market Analysis

$ 3999

The France Neurology Clinical Trials market is projected to grow from $279.3 Mn in 2022 to $371.1 Mn by 2030, registering a CAGR of 3.62% during the forecast period of 2022 - 2030. The market will be driven by the growing frequency of neurological diseases and the robust research infrastructure of France. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis International AG, Sanofi SA & Neuraxpharm France SAS.

ID: IN10FRCT005 CATEGORY: Clinical Trials GEOGRAPHY: France AUTHOR: Vidhi Upadhyay

Buy Now

France Neurology Clinical Trials Market Executive Summary

The France Neurology Clinical Trials market is projected to grow from $279.3 Mn in 2022 to $371.1 Mn by 2030, registering a CAGR of 3.62% during the forecast period of 2022 - 2030. The universal hybrid healthcare system in France is regarded as one of the best in the world, providing high-quality medical treatment. Healthcare expenditures in France are borne by both the state and the individual. In 2020, healthcare spending in France was comparable to 12.2% of GDP, greater than in any other EU Member State. Over 1,175,000 individuals in France have Alzheimer's disease, and over 200,000 more are identified with Alzheimer's or another dementia each year. France was the first European country to adopt a national Alzheimer's disease strategy.

Neurology clinical trials are a significant area of study in France, with several top pharmaceutical firms and research organisations undertaking studies in this subject. The French government has also aggressively promoted clinical research, with projects such as the French Clinical Trials Infrastructure Network (F-CRIN) aimed at bolstering the country's status as a clinical research centre. In recent years, there has been a greater emphasis on creating therapies for neurological illnesses such as Alzheimer's, Parkinson's, and multiple sclerosis, which has resulted in an increase in neurology clinical trials in France. According to ClinicalTrials.gov, there are now over 1,500 active clinical studies in France, with many of them focusing on neurology.

France Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The expanding elderly population, as well as the frequency and incidence of nerve-related ailments among them, propels the neurological clinical trials market forward. The growing frequency of neurological diseases, as well as the high number of nerve injuries, demands the establishment of a neurology clinical trials industry. France has a robust research infrastructure, with a huge pool of qualified researchers and excellent facilities which is why market participants and researchers are increasingly focusing on expanding neurostimulation and neuromodulation technologies such as next-generation neurostimulation devices, firm collaborations to introduce enhanced products, and the forthcoming newest innovations. Government financing for neurological disease research hastened market expansion, which is expected to drive market growth.

Market Restraints

The clinical trial regulatory environment in France is complicated, with strong restrictions and criteria for ethical and safety issues. This might make it tough for firms to launch and perform clinical studies in the nation. Clinical trials are expensive and need substantial finance, which can be difficult for smaller businesses or research organisations with few resources. Other nations, such as the United States and China, are also actively investing in clinical research and recruiting major pharmaceutical corporations and research institutes posing good competition.

Competitive Landscape

Global Key Players

Pfizer Inc.
Novartis International AG
Sanofi SA
Merck & Co. Inc.
AbbVie Inc.
Biogen Inc.
Roche Holding AG
Eli Lilly and Company
AstraZeneca PLC
Teva Pharmaceutical Industries Ltd.

Local Key Players

BrainVectis - is dedicated to the research and development of medicines for neurodegenerative disorders such as Huntington's and Alzheimer's
Ipsen - is a worldwide, mid-sized biopharmaceutical firm dedicated to developing breakthrough therapies in cancer, rare diseases, and neurology
LFB Biotechnologies - LFB is a biopharmaceutical business that researches, produces, and sells plasma-derived medical products and recombinant proteins for the treatment of patients suffering from severe and usually rare diseases
BioSerenity - is a cutting-edge medical technology firm that specialises in smart healthcare solutions for Sleep Medicine, Neurology, and Cardiology
Neuraxpharm France SAS - is a renowned European specialized pharmaceutical firm focusing on the treatment of illnesses of the central nervous system (CNS)

Notable Insights

August 2022, The National Agency for the Safety of Medicines and Health Products (ANSM) in France has authorized BrainVectis permission to begin enrolling patients for a phase 1/2 clinical study of their experimental adeno-associated virus (AAV) gene therapy for the treatment of early-stage Huntington illness.

Healthcare Policies and Regulatory Landscape & Reimbursement Scenario

Clinical trials are monitored in France by the French National Agency for Medical and Health Products Safety (ANSM) and the French Committee for the Protection of Persons (CPP). The ANSM is in charge of assessing, monitoring, and regulating pharmaceutical goods, whereas the CPP is in charge of ethical assessment and approval of clinical studies involving human subjects.

Neurology clinical trials in France are primarily financed by pharmaceutical firms or academic institutions, and they must adhere to the ANSM and CPP criteria. The ANSM examines the treatment's safety and efficacy and authorises the study before it can begin, whereas the CPP reviews the trial protocol and assures that it fulfils ethical and legal criteria.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.